C1-esterase inhibitor protects against neointima formation after arterial injury in atherosclerosis-prone mice.
BACKGROUND
Although activation of the complement system has been implicated in the progression of human atherosclerosis, its function during arterial remodeling after injury has not been investigated. Here, we examined the contribution of the complement cascade to neointima formation in apolipoprotein E-deficient mice using a C1-esterase inhibitor (C1-inhibitor).


RESULTS
Apolipoprotein E-deficient mice fed an atherogenic diet were subjected to wire-induced endothelial denudation of the carotid artery and treated with C1-inhibitor (Berinert; 15 IU i.v.) or vehicle perioperatively and subsequently every 2 days. The effectiveness of C1-inhibitor treatment was confirmed by measurement of plasma C1-inhibitor activity. A significant reduction in serum triglyceride levels was observed in C1-inhibitor-treated mice, whereas cholesterol levels did not differ. After 3 weeks, neointimal area was significantly reduced in C1-inhibitor-treated mice versus controls, whereas medial area was unaltered. This was associated with a significant decrease in neointimal and medial macrophage and CD3+ T-cell content. Expression of C3 mRNA was significantly reduced in plaques of C1-inhibitor-treated mice 10 days after injury, as assessed by reverse-transcription polymerase chain reaction. The peak in serum C3 levels after injury was markedly downregulated by C1-inhibitor, as evidenced by ELISA. Immunohistochemistry revealed strong expression of C3 and C3c, which colocalized to plaque macrophages and was reduced in C1-inhibitor-treated mice. C1-inhibitor impaired monocyte arrest on activated endothelium and platelets under flow conditions in vitro and leukocyte recruitment to carotid arteries 1 day after injury in vivo.


CONCLUSIONS
C1-inhibitor limits neointimal plaque formation and inflammation. This may involve blockade of complement activation, inhibition of leukocyte recruitment, and reduced triglyceride levels, thus providing a multimodal approach to treat arterial disease.
Shagdarsuren
Erdenechimeg
E
Institute of Molecular Cardiovascular Research, University Hospital, RWTH Aachen University, Aachen, Germany.
Bidzhekov
Kiril
K
Djalali-Talab
Yassin
Y
Liehn
Elisa A
EA
Hristov
Mihail
M
Matthijsen
Robert A
RA
Buurman
Wim A
WA
Zernecke
Alma
A
Weber
Christian
C
D000818:Animals; D001057:Apolipoproteins E / Q000172:deficiency; D001158:Arteries / Q000293:injuries* / Q000473:pathology; D050197:Atherosclerosis / Q000209:etiology / Q000517:prevention & control*; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D003167:Complement Activation / Q000187:drug effects; D050718:Complement C1 Inhibitor Protein / Q000494:pharmacology*; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000293:injuries / Q000473:pathology; D007249:Inflammation / Q000517:prevention & control; D051379:Mice; D012038:Regeneration / Q000187:drug effects*; D014280:Triglycerides / Q000097:blood; D017539:Tunica Intima / Q000473:pathology*
D001057:Apolipoproteins E; D050718:Complement C1 Inhibitor Protein; D014280:Triglycerides